GALAPAGOS NV (GXE.DE) Fundamental Analysis & Valuation
FRA:GXE • BE0003818359
Current stock price
24.38 EUR
-0.18 (-0.73%)
Last:
This GXE.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. GXE.DE Profitability Analysis
1.1 Basic Checks
- In the past year GXE was profitable.
- GXE had a negative operating cash flow in the past year.
- In multiple years GXE reported negative net income over the last 5 years.
- GXE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of GXE (9.42%) is better than 82.14% of its industry peers.
- Looking at the Return On Equity, with a value of 9.92%, GXE is in the better half of the industry, outperforming 77.38% of the companies in the same industry.
- The Return On Invested Capital of GXE (11.32%) is better than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| ROIC | 11.32% |
ROA(3y)5.36%
ROA(5y)1.9%
ROE(3y)6.68%
ROE(5y)1.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 28.85%, GXE belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 47.04%, GXE belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 97.33%, GXE belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
- GXE's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 47.04% | ||
| PM (TTM) | 28.85% | ||
| GM | 97.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
2. GXE.DE Health Analysis
2.1 Basic Checks
- GXE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- GXE has about the same amout of shares outstanding than it did 1 year ago.
- GXE has more shares outstanding than it did 5 years ago.
- GXE has a better debt/assets ratio than last year.
2.2 Solvency
- GXE has an Altman-Z score of 7.60. This indicates that GXE is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of GXE (7.60) is better than 80.95% of its industry peers.
- GXE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- GXE's Debt to Equity ratio of 0.00 is amongst the best of the industry. GXE outperforms 90.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.6 |
ROIC/WACC1.43
WACC7.91%
2.3 Liquidity
- A Current Ratio of 20.15 indicates that GXE has no problem at all paying its short term obligations.
- GXE's Current ratio of 20.15 is amongst the best of the industry. GXE outperforms 97.62% of its industry peers.
- GXE has a Quick Ratio of 20.00. This indicates that GXE is financially healthy and has no problem in meeting its short term obligations.
- GXE has a better Quick ratio (20.00) than 97.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 20.15 | ||
| Quick Ratio | 20 |
3. GXE.DE Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 334.82% over the past year.
- The Revenue has grown by 280.53% in the past year. This is a very strong growth!
- GXE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.97% yearly.
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.22%
3.2 Future
- The Earnings Per Share is expected to decrease by -25.26% on average over the next years. This is quite bad
- GXE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -30.71% yearly.
EPS Next Y-141.18%
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
EPS Next 5Y-25.26%
Revenue Next Year0.26%
Revenue Next 2Y-2.91%
Revenue Next 3Y-9.92%
Revenue Next 5Y-30.71%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. GXE.DE Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 5.01, the valuation of GXE can be described as very cheap.
- GXE's Price/Earnings ratio is rather cheap when compared to the industry. GXE is cheaper than 95.24% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.34, GXE is valued rather cheaply.
- GXE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.01 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -7.42 |
4.3 Compensation for Growth
- A cheap valuation may be justified as GXE's earnings are expected to decrease with -45.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
5. GXE.DE Dividend Analysis
5.1 Amount
- GXE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GXE.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:GXE (4/10/2026, 7:00:00 PM)
24.38
-0.18 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2026-02-24/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners25.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.61B
Revenue(TTM)1.11B
Net Income(TTM)320.88M
Analysts52.22
Price Target30.22 (23.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9817.73%
Min EPS beat(2)-19965.4%
Max EPS beat(2)329.9%
EPS beat(4)1
Avg EPS beat(4)-5598.11%
Min EPS beat(4)-19965.4%
Max EPS beat(4)329.9%
EPS beat(8)4
Avg EPS beat(8)-2634.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)487.56%
Min Revenue beat(2)-2.86%
Max Revenue beat(2)977.98%
Revenue beat(4)2
Avg Revenue beat(4)242.3%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)977.98%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.62%
PT rev (3m)-1.68%
EPS NQ rev (1m)-16.45%
EPS NQ rev (3m)-16.45%
EPS NY rev (1m)18.36%
EPS NY rev (3m)-9.64%
Revenue NQ rev (1m)-0.4%
Revenue NQ rev (3m)-0.4%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)-0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.01 | ||
| Fwd PE | N/A | ||
| P/S | 1.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.5 | ||
| P/tB | 0.5 | ||
| EV/EBITDA | -7.42 |
EPS(TTM)4.87
EY19.98%
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-4.12
FCFYN/A
OCF(TTM)-3.91
OCFYN/A
SpS16.88
BVpS49.1
TBVpS49.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number73.35
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| ROCE | 16.08% | ||
| ROIC | 11.32% | ||
| ROICexc | 144.09% | ||
| ROICexgc | 144.57% | ||
| OM | 47.04% | ||
| PM (TTM) | 28.85% | ||
| GM | 97.33% | ||
| FCFM | N/A |
ROA(3y)5.36%
ROA(5y)1.9%
ROE(3y)6.68%
ROE(5y)1.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
F-Score6
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 24.8% | ||
| Cap/Sales | 1.25% | ||
| Interest Coverage | 1127.48 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 20.15 | ||
| Quick Ratio | 20 | ||
| Altman-Z | 7.6 |
F-Score6
WACC7.91%
ROIC/WACC1.43
Cap/Depr(3y)83.14%
Cap/Depr(5y)94.58%
Cap/Sales(3y)13.02%
Cap/Sales(5y)12.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
EPS Next Y-141.18%
EPS Next 2Y-67.16%
EPS Next 3Y-45.56%
EPS Next 5Y-25.26%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.22%
Revenue Next Year0.26%
Revenue Next 2Y-2.91%
Revenue Next 3Y-9.92%
Revenue Next 5Y-30.71%
EBIT growth 1Y377.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.82%
EBIT Next 3Y8.25%
EBIT Next 5Y15.02%
FCF growth 1Y32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.55%
OCF growth 3YN/A
OCF growth 5YN/A
GALAPAGOS NV / GXE.DE Fundamental Analysis FAQ
What is the ChartMill fundamental rating of GALAPAGOS NV (GXE.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to GXE.DE.
What is the valuation status for GXE stock?
ChartMill assigns a valuation rating of 2 / 10 to GALAPAGOS NV (GXE.DE). This can be considered as Overvalued.
How profitable is GALAPAGOS NV (GXE.DE) stock?
GALAPAGOS NV (GXE.DE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of GALAPAGOS NV (GXE.DE) stock?
The Price/Earnings (PE) ratio for GALAPAGOS NV (GXE.DE) is 5.01 and the Price/Book (PB) ratio is 0.5.